Various oncogenic pathways such as EGFR, PI3K, AKT, JAK, MYC and ALK have been recently implicated in tumor immunology aside from their cell‐autonomous tumorgenicity roles: affecting the function of CD8+ T cells, NK cells, macrophages, and myeloid‐derived suppressor cells (MDSCs) in TME via regulating PD‐L1 expression, ultimately contributes to tumor immune escape and drug resistance.[29] Here, we showed that the absence of STK24 in tumor cells results in a suppression of PD‐L1 expression. The gene discussed is EGFR; the disease is neoplasm.